Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.19 USD | +0.97% | -1.70% | -62.77% |
May. 31 | Verve Therapeutics Names Troy Lister Chief Scientific Officer | MT |
May. 31 | Verve Therapeutics, Inc. Announces Executive Changes | CI |
Financials (USD)
Sales 2024 * | 15.25M | Sales 2025 * | 11.36M | Capitalization | 436M |
---|---|---|---|---|---|
Net income 2024 * | -224M | Net income 2025 * | -260M | EV / Sales 2024 * | -1.05 x |
Net cash position 2024 * | 452M | Net cash position 2025 * | 228M | EV / Sales 2025 * | 18.3 x |
P/E ratio 2024 * |
-1.94
x | P/E ratio 2025 * |
-1.83
x | Employees | 255 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.3% |
Latest transcript on Verve Therapeutics, Inc.
1 day | +0.97% | ||
1 week | -1.70% | ||
1 month | -13.50% | ||
3 months | -68.14% | ||
6 months | -55.98% | ||
Current year | -62.77% |
Managers | Title | Age | Since |
---|---|---|---|
Sekar Kathiresan
FOU | Founder | 52 | 17-12-31 |
Allison Dorval
DFI | Director of Finance/CFO | 48 | 21-11-28 |
Andrew Ashe
PSD | President | 57 | 18-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Burt Adelman
FOU | Founder | 71 | 17-12-31 |
Lonnel Coats
BRD | Director/Board Member | 58 | 22-08-07 |
Michael MacLean
BRD | Director/Board Member | 58 | 21-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.13% | 2 M€ | -25.75% | ||
3.54% | 0 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 5.19 | +0.97% | 1,545,632 |
24-05-30 | 5.14 | +1.18% | 1,582,606 |
24-05-29 | 5.08 | -3.05% | 1,842,793 |
24-05-28 | 5.24 | -0.76% | 1,266,081 |
24-05-24 | 5.28 | -0.94% | 934,439 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.77% | 436M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- VERV Stock